HYPEЦена Hyperliquid

HYPE surged 26.86%, nearing its all-time high. The primary catalyst is news that former President Trump stated U.S. CFTC Chairman Michael Selig is actively working to bring the Hyperliquid protocol into the U.S. in a fully compliant manner. This aligns with Hyperliquid's own lobbying efforts, including a recent proposal with trade.xyz to the SEC for introducing pre-IPO perpetual contracts (IPOPs) to provide price discovery before public listings. Key points driving the optimism include: Hyperliquid's established position as a leading on-chain perpetual exchange; active engagement with U.S. regulators (SEC and CFTC) on frameworks for compliant derivatives trading; and significant political and regulatory momentum under the current administration to foster crypto innovation with clearer rules. Potential paths for Hyperliquid's U.S. entry are discussed: 1) Partnering with licensed U.S. entities for clearing and KYC, 2) Listing Hyperliquid assets on already compliant platforms like Coinbase, or 3) The more complex route of acquiring/building a fully regulated U.S. exchange. The process is estimated to take several months to a year but marks a significant step towards legitimizing on-chain derivatives in the U.S. market, boosting HYPE's price prospects.

The price of the HYPE token surged by over 22% in the last 24 hours, nearing its all-time high, following comments from former President Donald Trump. Trump stated that CFTC Chairman Michael Sellig is working to bring the Hyperliquid futures exchange to the U.S. market "in full compliance with the law." The platform's growing popularity for 24/7 access to assets like oil, coupled with a broader cryptocurrency market rally—with Bitcoin and Ethereum also posting significant gains—further contributed to the token's sharp increase.

Former US President Donald Trump, during a White House meeting with leaders from crypto, tech, and financial firms on August 19, specifically mentioned CFTC Chairman Michael Selig's work on the Hyperliquid project. Trump's remarks focused on efforts to bring Hyperliquid to the US market compliantly. Attendees included executives from Coinbase, Ripple, Robinhood, SEC, Kraken, Gemini, Cboe, and ICE. Following Trump's comments, Hyperliquid's native token, $HYPE, surged roughly 20-25% within 24 hours, trading between $70-$73, nearing its June 2026 all-time high of over $76. Its market cap approached $18 billion, with daily trading volume exceeding $1.3 billion, ranking it 9th among tokens. However, Trump's statement did not announce any regulatory approval, CFTC registration, or specific US launch timeline. Hyperliquid's main interface still blocks US users, meaning traders were betting on a potential regulatory breakthrough, not a finalized deal. Hyperliquid is a blockchain built for trading, specializing in perpetual futures. It matches orders directly on-chain, aiming for centralized exchange speed while maintaining DeFi transparency and self-custody. At times, it has handled 40-70% of decentralized perpetual futures trading volume. The $HYPE token, launched via an airdrop in November 2024, is central to the network's economics. A significant portion of protocol fees goes to a buyback fund, creating sustained demand for the token. Trump's endorsement is seen as a catalyst for potential US market access, which could open the platform to institutional traders. Shares of Nasdaq-listed Hyperliquid Strategies, centered around $HYPE holdings, also jumped 30-31%, while shares of traditional derivatives operators like Cboe and CME fell. The path to a US launch remains a regulatory "minefield," involving unresolved issues on asset custody, leverage, market oversight, and customer protection. Traders now await concrete proposals from the CFTC, making $HYPE's recent gains dependent on follow-through actions after Trump's supportive signal.

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

The native token $HYPE of the derivatives exchange Hyperliquid is performing strongly in the bear market, termed by trader Pentosh1 as "the most profitable asset." This is attributed to Hyperliquid's revenue distribution model, which directs nearly all trading fees from its perpetual and spot markets to buy back and burn $HYPE tokens. Since November 2024, 462 million tokens worth ~$1.27B have been burned. The exchange handles 40-70% of decentralized perpetuals volume, with annual protocol revenue estimated at $600M-$950M. A key near-term catalyst is the upcoming launch of AQAv2 (Aligned Quote Asset v2) in 6 days. This mechanism will direct ~90% of the yield from over $5B in platform-held USDC reserves to the same buyback fund, potentially adding $135M-$160M in annual buyback volume. Coinbase and Circle are involved as treasury managers. $HYPE recently traded near its all-time high of $76.67. It saw a 20-25% surge after former President Donald Trump mentioned regulators were working to bring Hyperliquid into U.S. compliance, boosting its market cap to $18B. Analysts note the buyback mechanism scales with trading activity, not hype cycles, supporting its sustainability.